Tellgen Diagnostics July 13, 2023 Published in Shanghai
Tellgen Diagnostics
Committed to promoting the application of new testing technologies in the field of clinical laboratory testing. It has obtained nearly 300 medical device registration certificates, with flow fluorescence technology, chemiluminescence technology, multiplex fluorescent PCR technology and liquid chromatography-tandem mass spectrometry technology as the main technical platforms, covering tumors, autoimmunity, cardiovascular diseases, pathogen infections and reproductive health.
The 75th American Association for Clinical Chemistry (AACC) Annual Meeting & Clinical Lab Expo will be held at the Anaheim Convention Center in Anaheim, CA from July 25-27, 2023. Since its inception in 1949, AACC has become the largest and most influential international academic conference and clinical laboratory medical device expo in the world, attracting exhibitors from over 110 countries and regions with the latest in vitro diagnostic products.
At this exhibition, Tellgen will bring HPV full solution, chemiluminescence TESMI i100, TESMI i200 immunoassay analyzer and other star products of multiple platforms to AACC again. We sincerely invite global customers and partners to visit Booth 1389 for communication. Look forward to meeting you!
Let the exploration begin!
Time: July 25-27, 2023
Location: Anaheim Convention Center
Booth No.: 1389
Riding the wind and waves
Continuing the journey
See you on July 25-27!
Please visit Tellgen international website for product details: www.tellgencorp.com
Contact: [email protected]
Phone: 86-21-50862711
#About Us
Tellgen Corporation (referred to as “Tellgen”, stock code: 300642) was established in 2003 with its headquarters located in Zhangjiang Hi-Tech Park, Shanghai. It specializes in the R&D, production, promotion and sales of high-end in vitro diagnostic products, and is committed to promoting the application of new testing technologies in the field of clinical laboratory testing. It has obtained nearly 340 product registrations and approvals for medical devices. It has formed a series of products with flow fluorescence technology, chemiluminescence technology, multiplex fluorescent PCR technology and liquid chromatography-tandem mass spectrometry technology as the main technical platforms, and tumor full-course monitoring, autoimmunity, cardiovascular diseases, pathogen infections and reproductive health as the main application directions. It perfectly integrates flow fluorescence technology and chemiluminescence technology to form an “immune twin island” with a ceiling for detection speed. The fully automated mass spectrometry sample pretreatment system “eight steps in one instrument”. It has also launched a new generation of efficient assembly line – Fairy Express series, direct immunoassay assembly line – Tellgen Express T6 and efficient biochemical immune assembly line – Express T8, which truly achieves “Tellgen Express is efficient, saving half the space”.
Adhering to the concept of “connecting global technology resources and innovating based locally”, Tellgen strives to become a company with international influence in the field of life science and technology, and contribute to human health.